Prognostic and predictive biomarkers in melanoma

被引:8
作者
Maher, Nigel G. [1 ,2 ,3 ,4 ]
Vergara, Ismael A. [1 ,4 ,5 ]
Long, Georgina V. [1 ,4 ,5 ,6 ]
Scolyer, Richard A. [1 ,2 ,3 ,4 ,5 ,7 ]
机构
[1] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[2] Royal Prince Alfred Hosp, Tissue Pathol & Diag Oncol, Sydney, NSW, Australia
[3] NSW Hlth Pathol, Sydney, NSW, Australia
[4] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[5] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
[6] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
[7] Royal Prince Alfred Hosp, Tissue Pathol & Diag Oncol, Bldg 94 via John Hopkins Dr,Missenden Rd, Camperdown, NSW 2050, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
Melanoma; biomarkers; AMERICAN JOINT COMMITTEE; NODE-POSITIVE MELANOMA; STAGE IV MELANOMA; NEOADJUVANT IMMUNOTHERAPY; DESMOPLASTIC MELANOMA; PATHOLOGICAL RESPONSE; METASTATIC MELANOMA; CUTANEOUS MELANOMA; POOLED ANALYSIS; BRAF MUTATIONS;
D O I
10.1016/j.pathol.2023.11.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Biomarkers help to inform the clinical management of patients with melanoma. For patients with clinically localised primary melanoma, biomarkers can help to predict postsurgical outcome (including via the use of risk prediction tools), better select patients for sentinel lymph node biopsy, and tailor catch-all follow-up protocols to the individual. Systemic drug treatments, including immune checkpoint inhibitor (ICI) therapies and BRAF-targeted therapies, have radically improved the prognosis of metastatic (stage III and IV) cutaneous melanoma patients, and also shown benefit in the earlier setting of stage IIB/C primary melanoma. Unfortunately, a response is far from lished, and emerging, prognostic, and predictive pathological biomarkers that refine clinical decision-making in expression profile assays and nomograms are emerging astatic cutaneous melanoma, and the HLA-A*02:01 allele for the use of a bispecific fusion protein in metastatic uveal Australian clinical practice guidelines. Further research, validation, and assessment of clinical utility is required idly integrated into routine care.
引用
收藏
页码:259 / 273
页数:15
相关论文
共 179 条
  • [11] Final Version of 2009 AJCC Melanoma Staging and Classification
    Balch, Charles M.
    Gershenwald, Jeffrey E.
    Soong, Seng-jaw
    Thompson, John F.
    Atkins, Michael B.
    Byrd, David R.
    Buzaid, Antonio C.
    Cochran, Alistair J.
    Coit, Daniel G.
    Ding, Shouluan
    Eggermont, Alexander M.
    Flaherty, Keith T.
    Gimotty, Phyllis A.
    Kirkwood, John M.
    McMasters, Kelly M.
    Mihm, Martin C., Jr.
    Morton, Donald L.
    Ross, Merrick I.
    Sober, Arthur J.
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6199 - 6206
  • [12] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    Balch, CM
    Soong, SJ
    Gershenwald, JE
    Thompson, JF
    Reintgen, DS
    Cascinelli, N
    Urist, M
    McMasters, KM
    Ross, MI
    Kirkwood, JM
    Atkins, MB
    Thompson, JA
    Coit, DG
    Byrd, D
    Desmond, R
    Zhang, YT
    Liu, PY
    Lyman, GH
    Morabito, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3622 - 3634
  • [13] Bellomo D, 2020, JCO PRECIS ONCOL, V4, P319, DOI [10.1200/po.19.00206, 10.1200/PO.19.00206]
  • [14] Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma
    Bence, C.
    Hofman, V
    Chamorey, E.
    Long-Mira, E.
    Lassalle, S.
    Albertini, A. F.
    Liolios, I
    Zahaf, K.
    Picard, A.
    Montaudie, H.
    Lacour, J. P.
    Passeron, T.
    Andea, A. A.
    Ilie, M.
    Hofman, P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (05) : 984 - 994
  • [15] New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016
    Berk-Krauss, Juliana
    Stein, Jennifer A.
    Weber, Jeffrey
    Polsky, David
    Geller, Alan C.
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2020, 110 (05) : 731 - 733
  • [16] Bradford PT, 2009, ARCH DERMATOL, V145, P427, DOI 10.1001/archdermatol.2008.609
  • [17] A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging
    Brunner, Georg
    Heinecke, Achim
    Falk, Thomas M.
    Ertas, Beyhan
    Bloedorn-Schlicht, Norbert
    Schulze, Hans-Joachim
    Suter, Ludwig
    Atzpodien, Jens
    Berking, Carola
    [J]. JNCI CANCER SPECTRUM, 2018, 2 (03)
  • [18] Clinical Characteristics and Outcomes With Specific BRAF and NRAS Mutations in Patients With Metastatic Melanoma
    Bucheit, Amanda D.
    Syklawer, Erica
    Jakob, John A.
    Bassett, Roland L., Jr.
    Curry, Jonathan L.
    Gershenwald, Jeffrey E.
    Kim, Kevin B.
    Hwu, Patrick
    Lazar, Alexander J.
    Davies, Michael A.
    [J]. CANCER, 2013, 119 (21) : 3821 - 3829
  • [19] Darovasertib, a novel treatment for metastatic uveal melanoma
    Cao, Lei
    Chen, Shuzhen
    Sun, Rainie
    Ashby Jr, Charles R. R.
    Wei, Liuya
    Huang, Zoufang
    Chen, Zhe-Sheng
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [20] Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
    Carlino, M. S.
    Haydu, L. E.
    Kakavand, H.
    Menzies, A. M.
    Hamilton, A. L.
    Yu, B.
    Ng, C. C.
    Cooper, W. A.
    Thompson, J. F.
    Kefford, R. F.
    O'Toole, S. A.
    Scolyer, R. A.
    Long, G. V.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (02) : 292 - 299